After a series of staff consolidation moves in recent weeks, Novartis is again trimming its ranks, albeit in what appears to ...

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome (PWS) program after the FDA put a ...

Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year ...

Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its ...

Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.

As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...

Kyverna Therapeutics has officially started a rolling Biologics License Application submission to the FDA for miv-cel, keeping the candidate on track to be the first autoimmune CAR-T to reach the ...

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...

When Daniel Haders, Ph.D., was working in venture capital, he was on the hunt for an AI-driven drug discovery company that ...